Literature DB >> 19565264

The prognostic role of phospho-Src family kinase analysis in tongue cancer.

Ofer Ben-Izhak1, Victoria Cohen-Kaplan, Rafael M Nagler.   

Abstract

BACKGROUND: The up regulation of Phospho-Src family kinase oncogene has been correlated with reduced postoperative survival in various cancers but never in tongue cancer.
METHODS: We analyzed phospho-Src family kinase in 39 tongue (mobile) cancer patients by immunohistochemistry, compared these results with similar analysis for TUNEL and c-erbB-2 and with both clinical tumor characteristics and patient survival probability rates.
RESULTS: Phospho-Src family kinase overexpression was found in most tongue cancer biopsies (62%), significantly correlating with tumors larger in size (P = 0.05), progression—lymph node metastasis (0.004) and stage (P = 0.05), and correlating with TUNEL (P = 0.01) and c-erbB-2 (P = 0.05) expression rates. At 60 months, survival probability for negative phospho-Src family kinase level (=0) patients was 67%, but 30% for positive phospho-Src family kinase level (>0) patients (P = 0.05).
CONCLUSIONS: Inverse correlation between phospho-Src family kinase and patient survival demonstrates the prognostic role of phospho-Src family kinase in tongue cancer. These findings suggest a novel link between phospho-Src family kinase and TUNEL and c-erbB-2 pathways, tilting the balance toward cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19565264     DOI: 10.1007/s00432-009-0633-1

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  41 in total

1.  Carcinoma of the tongue: the speech therapist's perspective.

Authors:  M S Jackson; A A Wrench; D S Soutar; A G Robertson
Journal:  Br J Oral Maxillofac Surg       Date:  1999-06       Impact factor: 1.651

2.  Cancer of the mobile tongue in Finland--increasing incidence, but improved survival.

Authors:  O P Alho; S Kantola; U Pirkola; E Läärä; K Jokinen; E Pukkala
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

3.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity.

Authors:  T Akiyama; C Sudo; H Ogawara; K Toyoshima; T Yamamoto
Journal:  Science       Date:  1986-06-27       Impact factor: 47.728

Review 4.  Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases.

Authors:  Yuh-Ping Chong; Kim Kui Ia; Terrence D Mulhern; Heung-Chin Cheng
Journal:  Biochim Biophys Acta       Date:  2005-09-08

5.  Survival from head and neck cancer in Mumbai (Bombay), India.

Authors:  B B Yeole; R Sankaranarayanan; L Sunny M Sc; R Swaminathan; D M Parkin
Journal:  Cancer       Date:  2000-07-15       Impact factor: 6.860

6.  Two N-myristoyltransferase isozymes play unique roles in protein myristoylation, proliferation, and apoptosis.

Authors:  Charles E Ducker; John J Upson; Kevin J French; Charles D Smith
Journal:  Mol Cancer Res       Date:  2005-08       Impact factor: 5.852

Review 7.  Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.

Authors:  W Hanna; H J Kahn; M Trudeau
Journal:  Mod Pathol       Date:  1999-08       Impact factor: 7.842

8.  Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies.

Authors:  Rafael M Nagler; Hedviga Kerner; Shoshana Ben-Eliezer; Ira Minkov; Ofer Ben-Itzhak
Journal:  Oncology       Date:  2003       Impact factor: 2.935

9.  Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma.

Authors:  Ardeshir Hakam; Quan Fang; Richard Karl; Domenico Coppola
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

Review 10.  SRC family kinases: potential targets for the treatment of human cancer and leukemia.

Authors:  Markus Warmuth; Robert Damoiseaux; Yi Liu; Doriano Fabbro; Nathanael Gray
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

View more
  7 in total

1.  Expression of c-Src and phospho-Src in epithelial ovarian carcinoma.

Authors:  Yong-Wen Huang; Chen Chen; Man-Man Xu; Jun-Dong Li; Juan Xiao; Xiao-Feng Zhu
Journal:  Mol Cell Biochem       Date:  2013-01-01       Impact factor: 3.396

2.  FAK and Src expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.

Authors:  Stamatios Theocharis; Jerzy Klijanienko; Constantinos Giaginis; Paraskevi Alexandrou; Efstratios Patsouris; Xavier Sastre-Garau
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-10       Impact factor: 4.553

3.  Phosphorylated c-Src is a novel predictor for recurrence in cervical squamous cell cancer patients.

Authors:  Teng Hou; Juan Xiao; Huiting Zhang; Haifeng Gu; Yanling Feng; Jundong Li
Journal:  Int J Clin Exp Pathol       Date:  2013-05-15

4.  The prognostic significance of Src and p-Src expression in patients with osteosarcoma.

Authors:  Chao Hu; Zhouming Deng; Yi Zhang; Lei Yan; Lin Cai; Jun Lei; Yuanlong Xie
Journal:  Med Sci Monit       Date:  2015-02-28

5.  Facial cutaneo-mucosal venous malformations can develop independently of mutation of TEK gene but may be associated with excessive expression of Src and p-Src.

Authors:  Nabila Brahami; Selvakumar Subramaniam; Moudjahed Saleh Al-Ddafari; Cecile Elkaim; Pierre-Olivier Harmand; Badr-Eddine Sari; Gérard Lefranc; Mourad Aribi
Journal:  J Negat Results Biomed       Date:  2017-03-20

6.  Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma after Lung Resection.

Authors:  Shigeto Nishikawa; Toshi Menju; Koji Takahashi; Ryo Miyata; Makoto Sonobe; Akihiko Yoshizawa; Hiroshi Date
Journal:  Ann Thorac Cardiovasc Surg       Date:  2019-06-12       Impact factor: 1.520

7.  Anti-growth and pro-apoptotic effects of dasatinib on human oral cancer cells through multi-targeted mechanisms.

Authors:  Nam-Sook Park; Yu-Kyung Park; Anil Kumar Yadav; Young-Min Shin; David Bishop-Bailey; Jong-Soon Choi; Jong Wook Park; Byeong-Churl Jang
Journal:  J Cell Mol Med       Date:  2021-07-28       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.